287 related articles for article (PubMed ID: 16405921)
41. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
42. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Nagaya H; Satoh H; Kubo K; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
[TBL] [Abstract][Full Text] [Related]
43. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments).
Puscas I; Coltau M; Baican M; Domuta G
J Pharmacol Exp Ther; 1999 Aug; 290(2):530-4. PubMed ID: 10411559
[TBL] [Abstract][Full Text] [Related]
44. Biological basis of omeprazole therapy.
Sachs G; Wallmark B
J Gastroenterol Hepatol; 1989; 4 Suppl 2():7-18. PubMed ID: 2562365
[TBL] [Abstract][Full Text] [Related]
45. The H+/K+-ATPase inhibitory activities of Trametenolic acid B from Trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells.
Zhang Q; Huang N; Wang J; Luo H; He H; Ding M; Deng WQ; Zou K
Fitoterapia; 2013 Sep; 89():210-7. PubMed ID: 23742858
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.
Ushiro T; Tsukimi Y; Tanaka H
Jpn J Pharmacol; 1997 Nov; 75(3):303-6. PubMed ID: 9434264
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.
Thomson AB; Cohen P; Ficheux H; Fiorentini P; Domagala F; Homerin M; Taccoen A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1179-87. PubMed ID: 16611279
[TBL] [Abstract][Full Text] [Related]
48. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Mori H; Tonai-Kachi H; Ochi Y; Taniguchi Y; Ohshiro H; Takahashi N; Aihara T; Hirao A; Kato T; Sakakibara M; Kurebayashi Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):671-9. PubMed ID: 18981288
[TBL] [Abstract][Full Text] [Related]
49. H+/K+-ATPase inhibitors: a patent review.
Li H; Meng L; Liu F; Wei JF; Wang YQ
Expert Opin Ther Pat; 2013 Jan; 23(1):99-111. PubMed ID: 23205582
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
Galmiche JP; Sacher-Huvelin S; Bruley des Varannes S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2005 Mar; 21(5):575-82. PubMed ID: 15740541
[TBL] [Abstract][Full Text] [Related]
51. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins.
Matsuya H; Okamoto M; Ochi T; Nishikawa A; Shimizu S; Kataoka T; Nagai K; Wasserman HH; Ohkuma S
Biochem Pharmacol; 2000 Dec; 60(12):1855-63. PubMed ID: 11108801
[TBL] [Abstract][Full Text] [Related]
52. Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.
Tabuchi Y; Yashiro H; Hoshina S; Asano S; Takeguchi N
Br J Pharmacol; 2001 Dec; 134(8):1655-62. PubMed ID: 11739241
[TBL] [Abstract][Full Text] [Related]
53. HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule.
Liu P; Sun B; Lu X; Qin F; Li F
Biomed Chromatogr; 2007 Jan; 21(1):89-93. PubMed ID: 17080510
[TBL] [Abstract][Full Text] [Related]
54. Chemomechanical coupling in the gastric H,K ATPase.
Besancon M; Shin JM; Mercier F; Munson K; Rabon E; Hersey S; Sachs G
Acta Physiol Scand Suppl; 1992; 607():77-88. PubMed ID: 1333163
[TBL] [Abstract][Full Text] [Related]
55. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
56. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
57. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Scott DR; Munson KB; Marcus EA; Lambrecht NW; Sachs G
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1315-26. PubMed ID: 26423447
[TBL] [Abstract][Full Text] [Related]
58. ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase.
Urushidani T; Muto Y; Nagao T; Yao X; Forte JG
Am J Physiol; 1997 May; 272(5 Pt 1):G1122-34. PubMed ID: 9176222
[TBL] [Abstract][Full Text] [Related]
59. Functional consequences of the oligomeric form of the membrane-bound gastric H,K-ATPase.
Shin JM; Grundler G; Senn-Bilfinger J; Simon WA; Sachs G
Biochemistry; 2005 Dec; 44(49):16321-32. PubMed ID: 16331993
[TBL] [Abstract][Full Text] [Related]
60. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
